Zelgen(SH:688266) Xin Lang Zheng Quan·2025-11-20 05:24Core Viewpoint - Zai Lab's stock price has shown significant volatility, with a year-to-date increase of 64.82%, but a recent decline of 3.11% over the past five trading days, indicating potential market fluctuations and investor sentiment shifts [1][2]. Company Overview - Zai Lab, established on March 18, 2009, and listed on January 23, 2020, is based in Kunshan, Jiangsu Province, focusing on the research, production, and sales of chemical and biological new drugs [1]. - The company's main revenue source is pharmaceuticals, accounting for 99.97% of its business, with minimal contributions from intermediates and asset leasing [1]. Financial Performance - For the period from January to September 2025, Zai Lab reported a revenue of 593 million yuan, reflecting a year-on-year growth of 54.49%. However, the net profit attributable to shareholders was a loss of 93.42 million yuan, showing a slight increase in loss of 4.58% compared to the previous period [2]. Shareholder Structure - As of September 30, 2025, Zai Lab had 8,809 shareholders, a slight increase of 0.16% from the previous period. The average number of circulating shares per shareholder decreased by 0.16% to 30,049 shares [2]. - Notable institutional shareholders include China Europe Medical Health Mixed A and ICBC Frontier Medical Stock A, with varying changes in their holdings [2].